We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Analysis of Chromosome Abnormalities May Aid Diagnosis of Chronic Kidney Disease in Children

By LabMedica International staff writers
Posted on 04 May 2015
A recent paper discussed the possibility of using a panel of genetic abnormalities to aid in diagnosing children with chronic kidney disease (CKD).

CKD, which initially develops without specific symptoms and is generally only detected as an increase in serum creatinine or protein in the urine, causes serious illness in children, often leading to complications such as high blood pressure, heart disease, neurodevelopmental problems, and behavioral deficits. More...


Investigators at Columbia University (New York, NY, USA) noted that while there was frequent uncertainty in the identification of specific etiologies of CKD in children, recent studies had indicated that chromosomal microarrays could identify rare genomic imbalances that could clarify the etiology of neurodevelopmental and cardiac disorders in children.

To further elucidate the link between CKD and genomic anomalies, the investigators used Illumina (San Diego, CA, USA) microarrays to genotype 419 children enrolled in the Chronic Kidney Disease in Children (CKiD) Prospective Cohort Study to determine the prevalence of disease-causing copy number variations (CNVs) among various categories of pediatric CKD. The data for the patient population were compared with results obtained by genotyping 21,575 healthy pediatric and adult controls.

Results revealed significant CNVs in 31 (7.4%) of the 419 children with CKD (roughly ten-fold the percentage seen in the controls). The most frequent CNVs were deletions in the HNF1B (hepatocyte nuclear factor 1 homeobox B) gene. The protein encoded by this gene binds to DNA as either a homodimer, or a heterodimer with the related protein hepatocyte nuclear factor 1-alpha. The gene has been shown to function in nephron development, and regulates development of the embryonic pancreas. Mutations that block gene function result in renal cysts, diabetes syndrome, and noninsulin-dependent diabetes mellitus and expression of this gene is altered in some types of cancer.

“With conventional clinical findings, we often cannot determine the exact cause of CKD in children,” said senior author Dr. Ali G. Gharavi, professor of medicine at Columbia University. “However, our study shows that using a readily available genetic screening tool called chromosomal microarray analysis, it is possible in many cases to reach a more precise diagnosis and uncover information that can help define a patient’s risk for other disorders, such as autism or diabetes. Our findings should change clinical practice. Routine genetic screening of kids with CKD would not only improve diagnosis but also help identify those at risk for complications like diabetes and subclinical seizures, which benefit from early detection and treatment.”

The paper was published in the April 20, 2015, online edition of the Journal of Clinical Investigation.


Related Links:

Columbia University
Illumina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.